WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA(TM) (sitagliptin), the only DPP-4 inhibitor ...
The head-to-head comparison of four classes of medications assessed multiple metabolic, cardiovascular (CV), and safety outcomes for sulfonylurea glimepiride (Amaryl), the DPP-4 inhibitor sitagliptin ...
(Reuters) - An experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than Merck & Co's Januvia and an older common treatment, ...
Merck announced that expanded labeling has been approved for Januvia (sitagliptin), the only DPP-4 inhibitor indicated domestically as an adjunct to diet and exercise to improve glycemic control in ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...
Bristol-Myers Squibb/AstraZeneca’s Dapagliflozin Has the Potential to Challenge Bydureon on the Attribute of Weight Loss, According to Findings from Decision Resources BURLINGTON, Mass.--(BUSINESS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback